Open AccessSafety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study
Author(s) -
Hélio TedescoSilva,
Julio Pascual,
Ondřej Viklický,
Nikolina BašićJukić,
Élisabeth Cassuto,
Dean Y. Kim,
Josep M. Cruzado,
Claudia Sommerer,
Mohamed A. Bakr,
Valter Duro Garcı́a,
Uyen HuynhDo,
Graeme Russ,
Myoung Soo Kim,
Dirk Kuypers,
Matthias Büchler,
Franco Citterio,
Maria Pilar Hernandez Gutierrez,
Peter Bernhardt,
Steve Chadban
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002626
Subject(s) - everolimus , medicine , calcineurin , gastroenterology , mycophenolic acid , adverse effect , peripheral edema , tacrolimus , population , transplantation , urology , environmental health
The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail.